| abstract |
The present invention relates to: an insulin analog, wherein the insulin titer is reduced compared with a natural form and the binding force to an insulin receptor is reduced in order to increase the half-life of insulin in the blood; a conjugate, wherein the insulin analog and a carrier are connected; an extended release preparation containing the conjugate; and a method for preparing the conjugate. |